אוטרוגסטן 200 - Utrogestan 200
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | ||||||
|---|---|---|---|---|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | G03DA Pregnen-(4) derivatives | |||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||
| צ×רת ××ª× | ×××× ××, פ××× - VAGINAL; PER OS | |||||
| צ×רת ××× ×× | קפס×××ת, CAPSULES ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||
| ×ת×××× | Vaginal administration: Progesterone substitution for ovary deprived women in situation of total progesterone deficiency. Supplementation of the luteal phase during in vitro fertilization cycles. Supplementation of the luteal phase during spontaneous or induced cycles, in cases of hypofertility or primary or secondary ovarain failure, particulary through dysovulation. In cases of threatning abortion or prevention of repeated abortions due to proven luteal insufficiency. For all other progesterone indication, in the case of : Adverse events due to progesterone, contraindication of the oral route of administration hepatopathy. Vaginal or oral addministration: Disorders related to progesterone deficit in particular menopause ( in association with estrogen therapy).
| |||||
× ×ª×× × ×¡× [ ×צ×× ]
| ||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
 Â
| |||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| ×××ר××ס×× 200 ××××ר ××©×¨× ××ר×××ת
×××ר××ס×× 200 ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | BESINS-INTERNATIONAL LABORATORIES, FRANCE |
| ×©× ××¢× ×ר×ש×× | CTS LTD |
| ר×ש××× | ת×ר×× ××ש×: 1/2003. ר×ש××× ×ת×ר××: 06/2016 |
| ת×ר×× ×¢×××× ××ר×× | 15/05/19 |